Agilent Technologies, Inc. (A)
Agilent Technologies makes analytical instruments and lab services for chemical, pharmaceutical, and life-sciences customers.
Health Care stock comparison
A vs VTRS: which business are you actually underwriting?
Compare Agilent Technologies, Inc. with Viatris Inc. using their business models, SEC classifications, fiscal calendars, current primary filings, and the research questions that matter. This is a thesis framework—not a price target or automatic winner.
- Sector
- Health
- Industry
- Different SIC
- Shared themes
- 2
- Updated
- 2026-02-26
A vs VTRS: quick comparison
| Company fact | A | VTRS |
|---|---|---|
| Company | Agilent Technologies, Inc. | Viatris Inc. |
| Exchange | NYSE | NASDAQ |
| Headquarters | Not recorded | Not recorded |
| Founded | Not recorded | Not recorded |
| SEC industry | Laboratory Analytical Instruments | Pharmaceutical Preparations |
| Fiscal year-end | October 31 | December 31 |
| Latest annual filing | 10-K · 2025-12-22 | 10-K · 2026-02-26 |
How the businesses differ
Viatris Inc. (VTRS)
Viatris makes generic and branded medicines distributed across global markets.
The useful starting point is not which ticker has performed better. It is whether the two companies convert the same economic forces into revenue and cash flow in the same way. A is classified by the SEC as Laboratory Analytical Instruments, while VTRS is classified as Pharmaceutical Preparations. The different industry codes are a warning against treating sector membership as proof of identical economics.
Which thesis does each company fit?
Use the distinction below to decide which filing deserves deeper work. It is a research routing rule, not a recommendation or prediction.
Study A when…
- Drug approvals and clinical-trial readouts
- Medicare and drug-pricing policy
- Demographics and an aging population
- GLP-1 and obesity-drug demand
Study VTRS when…
- Drug approvals and clinical-trial readouts
- Medicare and drug-pricing policy
- Demographics and an aging population
- GLP-1 and obesity-drug demand
Shared research themes
US marketsInternational markets
SEC filing comparison and disclosure evidence
Start with primary filings because fiscal calendars and accounting presentation can make superficially similar quarters incomparable.A's fiscal year ends October 31, while VTRS's ends December 31. Normalize the reporting periods before comparing growth, margins, capital intensity, or guidance.
The current verified House Clerk snapshot contains 0matched transaction rows for Aand 0 for VTRS. These delayed, range-based disclosures can identify a filing to inspect; they do not establish motive, conviction, or a real-time trading signal.
A primary filings
VTRS primary filings
What this comparison cannot tell you
This page does not contain licensed live prices, a valuation model, earnings estimates, portfolio constraints, or a forecast of future returns. SEC classifications can be broad, company descriptions can lag strategic change, and the latest annual filing may predate a material acquisition or divestiture. Read subsequent quarterly and current reports before making a decision.
A stronger business is not automatically the better stock. Starting valuation, expectations, capital structure, cyclicality, dilution, and the probability of each thesis determine the investment outcome. Use this comparison to frame the work, then verify the numbers in the linked filings and current company disclosures.
More comparisons involving A or VTRS
A vs VTRS FAQs
Are A and VTRS direct competitors?
Agilent Technologies, Inc. and Viatris Inc. sit in the same Health Care sector but have different SEC industry classifications. The comparison is most useful for portfolio role and sector exposure, not as a claim that every product competes directly.
Which is better, A or VTRS?
There is no context-free winner. Compare the operating exposures, filing evidence, valuation, balance sheet, and risks against the specific thesis you are testing. This page deliberately does not turn a static profile into a buy or sell recommendation.
Does this A vs VTRS comparison include live prices?
No. Yield Theory does not republish unlicensed real-time market data. Use a regulated broker or licensed quote provider for current prices, then use the primary filings here to test the business thesis.
Where does the company information come from?
Company classifications, fiscal year-ends, and filing links come from the SEC EDGAR submissions API snapshot refreshed 2026-08-10. Business summaries and research themes are maintained by Yield Theory.
Data snapshot: SEC EDGAR submissions API, refreshed 2026-08-10. Independent educational research; not investment advice.
Go beyond A vs VTRS.
Yield Theory connects filings, capital flows, catalysts, and risks into an investable research process.
$15/mo or $150/yr · cancel future renewals anytime · sources included